id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-307925-0nhsf90c	Ordóñez‐Rubiano, Maria Fernanda	Dupilumab in atopic dermatitis, a protocol for SARS‐COV 2 infected patients	2020-08-10		.txt	text/plain	767	56	53	During SARS-COV 2 pandemic scarce articles have been written regarding the possible effects of biologics and immunosuppressants in chronic inflammatory skin diseases, such as atopic dermatitis (AD) 1 . Therefore, it is important as dermatologist to be involved in health care of infected or COVID-19 patients having severe dermatological diseases and making appropriate decisions for their skin health. On May 18th, 2020 he was diagnosed with asymptomatic SARS-COV 2 by PCR due to occupational exposure, to our knowledge the first patient in Latin America infected while in treatment with dupilumab. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab European Task Force on Atopic Dermatitis (ETFAD) statement on severe This article is protected by copyright. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single center real-life experience Figure 1: Protocol for atopic dermatitis In patients treated with dupilumab This article is protected by copyright.	./cache/cord-307925-0nhsf90c.txt	./txt/cord-307925-0nhsf90c.txt